What happenedRaised $315M in Series D funding, led by Ally Bridge Group and Alpha Wave.
The company said the funding supports advance ADVC001, its novel Lead-212 PSMA-targeted radioligand therapy for metastatic prostate cancer toward Phase 3 development, expand vertically integrated radiopharmaceutical platform and manufacturing infrastructure, and accelerate its growing pipeline of targeted alpha therapies Led by CEO Philina Lee, AdvanCell is a clinical-stage radiopharmaceutical company developing new targeted alpha the.
Likely next InferredNew market entryFirst local hires in the new marketLocal entity and legal setup
Where you helpCommercial leadershipOperations hiringGo-to-market partnershipsMarket-entry advisersLocal employment infrastructure
Approach preferences not yet specified